Dolutegravir-based ART shows no evidence of excessive weight gain or increased adiposity compared to efavirenz or protease inhibitor-based regimens in children and adolescents over a five-year period.
Metabolic health parameters, including total cholesterol, triglycerides, and glucose levels, were significantly more favorable in participants receiving dolutegravir.
Findings provide robust evidence supporting the World Health Organization recommendation of dolutegravir as the preferred antiretroviral for pediatric populations.
Background: Addressing the Weight Gain Concern in Pediatric HIV
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.